Immunovaccine Inc., of Halifax, Nova Scotia, reported results from a Phase I study showing that all ovarian cancer patients receiving cancer vaccine DPX-Survivac who were evaluable by tetramer staining produced survivin-specific CD8 T cells following one or two vaccinations...The Phase Ib portion will enroll all patients with solid tumors, while the Phase IIa portion will enroll gastric and breast cancer patients

Total: $161.9M Year to Date: $760.84M Company (Location) Partner (Location) Amt. (M) Details Date Active Biotech AB (Lund, Sweden) Ipsen SA (Paris) €10 ($12.9) For fully enrolling the Phase III trial of tacrolimus 12/11/12 Algeta ASA (Oslo, Norway) Bayer AG (Leverkusen, Germany) €50 ($65.7) For the submission of a marketing authorization application to the European Medicines Agency for Alpharadin to treat castration-resistant prostate cancer patients with bone metastases 12/13/12 Anacor

The events-driven trial in chemotherapy-naïve castration-resistant prostate cancer patients is expected to be complete toward the end of 2013

For use in combination with carboplatin for first-line treatment of locally advanced or metastatic non-small-cell lung cancer in patients who are not candidates for surgery or radiation (2/4) Isis Pharmaceuticals Inc...Oral mucositis in cancer patients (12/06) Acorda Therapeutics Inc

CYT-6091, which is comprised of gold nanoparticles bound with an immune avoiding molecule (PEG-Thiol) and tumor necrosis factor alpha (TNF), has been successfully tested at the National Cancer Institute in a Phase I trial in advanced-stage cancer patients

While superoxide plays a role in many diseases, Galera has decided to initially pursue development of a dismutase mimetic in mucositis caused by radiation in head and neck cancer patients

CYT-6091 , which is comprised of gold nanoparticles bound with an immune avoiding molecule (PEG-Thiol) and tumor necrosis factor alpha (TNF), has been successfully tested at the National Cancer Institute in a Phase I trial in advanced-stage cancer patients

weekly dosing for cancer patients, using dosages two to four times higher than what the FDA had approved, Marshall Miller, acting U.S...Until the FDA ordered a boxed warning in 2007 against the use of Aranesp to treat anemia in cancer patients not undergoing chemotherapy due to an increased risk of death, the company promoted that off-label use, according to the Department of Justice (DOJ

MDACC researchers used phage display in terminally ill cancer patients to establish a library of peptides that targeted not only tumors but also specific healthy tissue

MDACC researchers used phage display in terminally ill cancer patients to establish a library of peptides that targeted not only tumors but also specific healthy tissue

weekly dosing for cancer patients – even though the FDA had refused to approve those regimens and the higher dosages they required

Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, submitted a marketing authorization application to the European Medicines Agency for Alpharadin (radium-223 dichloride) for the treatment of castration-resistant prostate cancer patients with bone metastases

GTx Inc., of Memphis, Tenn., attained its enrollment goal for both of its pivotal Phase III studies of enobosarm to prevent and treat muscle wasting in non-small-cell lung cancer patients

Algeta ASA, of Oslo, Norway, said partner Bayer AG, of Leverkusen, Germany, submitted a marketing authorization application to the European Medicines Agency for Alpharadin (radium-223 dichloride) for the treatment of castration-resistant prostate cancer patients with bone metastases

During the collaboration, HGS conducted Phase Ia trials of AEG40826 (formerly HGS1029) in cancer patients and collaborated with Pharmascience unit Aegera Therapeutics Inc

AstraZeneca plc, of London, said it agreed with the FDA on label changes for Faslodex (fulvestrant) injection, updating the label with results and a Kaplan-Meier plot of the final overall survival (OS) analysis from the CONFIRM pivotal study in recurrent or metastatic breast cancer patients...The four-week, repeat-dose study is designed to investigate the hypothesis that inhibition of hepcidin can raise hemoglobin levels in cancer patients with anemia

We are very pleased with the clinical data from what was a heavily treated breast cancer patient population," Anthony Marucci, president and CEO of Celldex, told BioWorld Today...According to estimates, about 20 percent of breast cancer patients have triple-negative disease, with about 35 percent of those patients expressing GPNMB

Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, said the FDA approved a broader indication for oral, once-daily Zytiga (abiraterone acetate), expanding its use in combination with prednisone for earlier-stage treatment in metastatic castration-resistant prostate cancer patients before the use of chemotherapy

Cancer Patient dosing was initiated in a Phase I trial 11/9/12 Coronado Biosciences Inc. (Burlington, Mass.) CNDO-109 CNDO-109-activated allogeneic NK cells Acute myeloid leukemia Started a Phase I/II dose-escalation trial of allogeneic natural killer cells activated by its CNDO-109 in patients in first complete remission from and who are deemed high risk for relapse from AML 11/29/12 CytRx Corp. (Los Angeles) Aldoxorubicin Tumor-targeting doxorubicin conjugate (formerly INNO-206) Advanced soft